PATTERNOX

growth-positive

The article provides an extensive analysis of the global medtech market, focusing on various surgical procedure volumes and device markets. It covers forecasts and trends from 2021 to 2031, offering insights into 23 major device markets and over 200 technology subsegments. The report is considered a gold standard for device market sizing data, aiding strategic decisions on commercialization and new product development. It includes detailed analyses of procedure volumes across multiple regions and countries, with updates and expansions made annually. The article also highlights competitive landscape analyses and key market events for strategics and startups, indicating a growth-positive impact on Life Science Intelligence.

growth-positive

Patternox, founded by Dr. Ophir Aharon, is developing an innovative imaging device to detect subcutaneous distortions, which can indicate early-stage skin cancer. The device uses electromagnetic field variations to create a topographic image beneath the skin, offering a non-invasive alternative to traditional methods that rely on color changes. Currently in the clinical trial phase, Patternox plans to advance its prototype to mass production and seek FDA approval. The company aims to integrate AI to automatically grade subcutaneous distortions, potentially benefiting both medical and cosmetic fields. Patternoxs approach represents a significant advancement in early skin cancer detection and cosmetic applications.

growth-positive

The article discusses פטרנוקס, a company founded by Dr. Ophir Aharon, which has developed a revolutionary device for early diagnosis of skin cancer. The device uses subsurface imaging to detect distortions beneath the skin, which can indicate cancer or cosmetic issues before they become visible. The technology is currently in the clinical trial stage, with tests conducted at the Skin Center in Florida. The device aims to become a gold standard in dermatology, with potential applications for dermatologists, general practitioners, cosmeticians, and home users. The company plans to integrate AI technology in the future.

growth-positive

Patternox, a medical technology company, has developed the PatScope scanner, a device that uses an algorithm to detect unique patterns of light movements in the skin, potentially identifying skin cancer at an early stage. The company has filed a US patent application and plans to launch a seed round in July to fund FDA approval and commercialization. The scanner is currently being tested in clinical trials, and the company envisions a future where patients can perform the scan at home with virtual assistance from their dermatologist. The technology could reduce unnecessary biopsies and has potential applications in monitoring skin changes in astronauts and cosmetic purposes. The focus of Patternox is on detecting skin cancer early and developing artificial intelligence to diagnose it based on the movement patterns detected by the PatScope.